Laddar populära aktier...
Redeye comments on Northbaze Q2 2024 report. The Q2 2024 report was better than expected with sales ...
Redeye raises its base case following the positive readout in the phase IIa RVO study with ANXV.
Solteq had released preliminary Q2 figures ahead of the earnings report and the comparable net sales...
Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequ...
Redeye comments on Better Collective’s Q2-results which were in line with expectations, albeit with ...
Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antib...
Redeye states that while the Q2 report was soft, it had some positive highlights - including the seq...
Redeye saw a report with sales that were in line with better-than-expected results.
Redeye updates its view on Flexion Mobile following its Q2 2024 report.
Rec. PTP beat on NOI-margins and hedging Expect call of hybrid bonds in September Report leads us to...
Redeye provides a preview for Integrum’s Q1 report, due on Thursday, August 29.
Q2 in line: sales up 11% y-o-y, adj. EBIT margin 37% (24%) Guides for -0.
Redeye gives an initial take on the positive phase IIa results in RVO with ANXV, an imporant milesto...
AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market.
Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are assoc...
